The U.S. Department of Health and Human Services (HHS) Office for Civil Rights (OCR) announced a civil enforcement program to implement and enforce federal confidentiality protections for substance use disorder patient records under 42 CFR Part 2. The initiative, tied to the Great American Recovery Initiative, brings civil penalties for non‑compliance with privacy rules, aligning Part 2 protections more closely with HIPAA standards.

In mid-January 2026, the federal government triggered a brief but jarring crisis for the addiction and behavioral health field when the U.S. Department of Health and Human Services abruptly canceled nearly $2 billion in Substance Abuse and Mental Health Services Administration (SAMHSA) grants that fund critical addiction treatment, mental health care, homelessness services, suicide prevention and workforce development programs nationwide.

A Science study highlighted by The Washington Post finds that the dramatic drop in U.S. fentanyl-related overdose deaths since mid-2023 may be linked to global supply disruptions—particularly China’s crackdown on chemicals used to manufacture illicit fentanyl. Overdose deaths had soared above 100,000 annually through 2022 but began declining in 2023 and continued into 2025, with synthetic-opioid deaths falling sharply. The researchers point to reduced precursor supply, lower fentanyl purity, and online reports of fentanyl shortages as key indicators of market stress.

The JAMA Psychiatry cohort study evaluates the role of cigarette smoking transitions in long-term recovery from substance use disorders (SUDs), offering vital insights for clinicians, treatment programs, and addiction researchers. Using data from the nationally representative PATH Study, researchers followed 2,652 adults with a history of SUD across multiple years to understand whether changing smoking behavior — specifically quitting cigarettes — is associated with sustained recovery from other addictive substances. 

In 2024, U.S. states and localities began spending opioid settlement funds — payments from companies implicated in the opioid crisis — to address addiction and overdose harms. These settlements, part of a broader national effort totaling more than $50 billion, offer an unprecedented but complex opportunity to strengthen systems of care. Researchers from KFF Health News, the Johns Hopkins Bloomberg School of Public Health, and Shatterproof catalogued over 10,500 individual expenditures in 2024, revealing how jurisdictions have allocated nearly $2.7 billion of settlement cash.

ARMR Sciences is preparing to launch the first major human clinical trial of a fentanyl vaccine, marking a potentially transformative development in efforts to prevent opioid overdose and reduce mortality linked to synthetic opioids. Unlike medications such as naloxone that reverse overdoses after they occur, this investigational vaccine is designed as a preventive intervention, training the immune system to produce antibodies that bind to fentanyl molecules in the bloodstream.